

# RECOMMENDATION BY HOSPITAL AUTHORITY'S OFFICE FOR PRIORITY REVIEW OF NEW DRUG APPLICATION UNDER "1+" MECHANISM

HA



1

## IDENTIFY PRODUCT

- Hospital Authority (HA) identifies drugs for cancer treatment (initial phase) for priority review, with priority given to:
  - local unmet medical need
  - cost-effectiveness, particularly for those evidenced by Health Technology Assessment (HTA) in HK
  - completed, ongoing or planned clinical trials within the Greater Bay Area(preferred)/local data available



HA



2

## CONNECT POTENTIAL APPLICANT

- HA connects with potential applicant for New Drug Application (NDA)
- Refer them to request for pre-NDA meeting with Department of Health (DH)
- Obtain its consent to notify DH

DH



3

## CONFIRM CRITERIA AND REGISTRATION REQUIREMENTS

- DH assesses regulatory criteria upon notification, based on:
  - "1+" mechanism eligibility criteria\*
  - pre-NDA meeting request
  - application status outside Hong Kong



HA



4

## DECIDE TO RECOMMEND PRODUCT

- Upon DH confirmation of eligibility, HA determines priority review recommendations
- If recommended, HA submits recommendation letter to DH

DH



5

## PRIORITY REVIEW

- DH screens application & HA's recommendation letter
- Evaluates accepted application with target cumulative time of **100 working days**.
- Applicant also has its target response time (see diagram of "Stop-clock Mechanism")

DH



6

## APPROVE BY REGISTRATION COMMITTEE

- Registration Committee\*\* approves application based on safety, efficacy and quality
- DH marks approved products as "Priority Review" on [Drug Database](#) for Pharmacy and Poisons Board

HA



7

## ENLIST IN HA FORMULARY

- Once pricing and other requirements are resolved, recommendation will be submitted within 120 calendar days for Drug Advisory Committee (DAC) review
- If recommended by DAC, enlistment will follow prevailing procedures and timelines



Evaluation time Expedited to within **100 working days#**



Important:  
Recommendation for priority review is only accepted before evaluation begins



\* Refer to Table 2 of <Guidance Notes on Registration of Pharmaceutical Products: New Drug Applications>  
\*\* Pharmacy and Poisons (Registration of Pharmaceutical Products and Substances) Committee

# Regular cumulative processing time for "1+" applications : within 150 working days.